{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:33:40Z","timestamp":1769744020293,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clml.2020.06.024","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T11:37:42Z","timestamp":1594035462000},"page":"e910-e925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib"],"prefix":"10.1016","volume":"20","author":[{"given":"Sudhir","family":"Manda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habte A.","family":"Yimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-0912","authenticated-orcid":false,"given":"Stephen J.","family":"Noga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saulius","family":"Girnius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-156X","authenticated-orcid":false,"given":"Christopher A.","family":"Yasenchak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"Charu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-6960","authenticated-orcid":false,"given":"Kimberly","family":"Bogard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renda H.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2629-6025","authenticated-orcid":false,"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Demers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vickie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Presley","family":"Whidden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Kambhampati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruemu E.","family":"Birhiray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haresh S.","family":"Jhangiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1518","authenticated-orcid":false,"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.06.024_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN guidelines insights: multiple myeloma, version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2020.06.024_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.06.024_bib3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.06.024_bib4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.06.024_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajh.23933","article-title":"Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study","volume":"90","author":"Mateos","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.06.024_bib6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00277-016-2901-x","article-title":"Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma","volume":"96","author":"Jimenez-Zepeda","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.06.024_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.06.024_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes","volume":"17","author":"Shah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.06.024_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.clml.2019.06.007","article-title":"Treatment patterns and clinical and economic outcomes in patients with newly diagnosed multiple myeloma treated with lenalidomide- and\/or bortezomib-containing regimens without stem cell transplant in a real-world setting","volume":"19","author":"Chari","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.06.024_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/17474086.2020.1729734","article-title":"Real-world outcomes and factors impacting treatment choice in relapsed and\/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd","volume":"13","author":"Chari","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2020.06.024_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/17474086.2016.1195254","article-title":"Real-world treatment patterns and associated progression-free survival in relapsed\/refractory multiple myeloma among US community oncology practices","volume":"9","author":"Jagannath","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2020.06.024_bib12","first-page":"2789","article-title":"Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life","volume":"23","author":"Baz","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2020.06.024_bib14","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.clml.2017.03.101","article-title":"The real-world characteristics and outcomes of newly diagnosed myeloma patients ineligible for clinical trials","volume":"17","author":"Fiala","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.06.024_bib15","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2019-125749","article-title":"Real-world (RW) multiple myeloma (MM) patients (Pts) remain under-represented in clinical trials based on standard laboratory parameters and baseline characteristics: analysis of over 3,000 Pts from the insight MM global, prospective, observational study","volume":"134","author":"Hungria","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.06.024_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40262-018-0702-1","article-title":"Clinical pharmacology of ixazomib: the first oral proteasome inhibitor","volume":"58","author":"Gupta","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clml.2020.06.024_bib18","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood-2018-99-113441","volume":"132","author":"Hajek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.06.024_bib19","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood-2019-126606","volume":"134","author":"Hajek","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.06.024_bib20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00277-020-03985-9","article-title":"Ixazomib-based regimens for relapsed\/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study","volume":"99","author":"Cohen","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.06.024_bib21","first-page":"786","article-title":"Real world use of ixazomib with lenalidomide and dexamethasone for patients with relapsed and relapsed refractory multiple myeloma","volume":"102","author":"Ziff","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.06.024_bib22","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood-2018-99-112046","article-title":"Treatment of relapsed and refractory multiple myeloma with fully oral triplet IRD (ixazomib, lenalidomide and dexamethasone) is safe and with significant therapeutic outcomes","volume":"132","author":"Minarik","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.06.024_bib23","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2019-128865","article-title":"Overall survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (RD) in RRMM patients treated in routine clinical practice: results from the Czech registry of monoclonal gammopathies (RMG)","volume":"134","author":"Minarik","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.06.024_bib24","first-page":"3087","article-title":"\u201cReal world\u201d data on the efficacy and safety of ixazomib in combination with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a combined study from the Greek, Czech and UK databases","volume":"130","author":"Terpos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.06.024_bib25","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.06.024_bib26","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.06.024_bib27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.06.024_bib28","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.06.024_bib29","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.06.024_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","article-title":"Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple myeloma","volume":"20","author":"Chari","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.06.024_bib31","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and\u00a0Friends of Cancer Research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.06.024_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-018-0106-3","article-title":"Phase 1\/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma","volume":"8","author":"Kumar","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.06.024_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2018.09.011","article-title":"All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"106","author":"Dimopoulos","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2020.06.024_bib34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.14733","article-title":"Management of adverse events associated with ixazomib plus lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"178","author":"Kumar","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.06.024_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1479-5868-8-80","article-title":"How many steps\/day are enough? For older adults and special populations","volume":"8","author":"Tudor-Locke","year":"2011","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.clml.2020.06.024_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2869.2007.00567.x","article-title":"The nature of spontaneous sleep across adulthood","volume":"16","author":"Campbell","year":"2007","journal-title":"J\u00a0Sleep Res"},{"key":"10.1016\/j.clml.2020.06.024_bib37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/NCC.0b013e3181f9904d","article-title":"Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma","volume":"34","author":"Coleman","year":"2011","journal-title":"Cancer Nurs"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020303359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020303359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:31Z","timestamp":1761870871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020303359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2152265020303359"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.06.024","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}